Why Phase III Still Matters
Executive Summary
Avycaz dosing for renally impaired patients was carefully considered based on sophisticated PK/PD analysis and Phase II data used to support its expedited limited use approval. Even so, the Phase III trials still uncovered a problem.
You may also be interested in...
Keeping Track: Novel Orphan Drugs Amondys 45, Nulibry Clear US FDA; First-Line NSCLC Claim For Libtayo
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Complexity Has Benefits: Data Show Biologics, Targeted Agents Have Better Approval Prospects
Biologics have 9.1% likelihood of making it through the clinic to approval, compared to 5.7% for new molecular entities, according to an analysis of 10 years of Biomedtracker drug development data by BIO, Informa Pharma Intelligence and QLS.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: